Zydus Lifesciences Limited has informed the Exchange regarding a press release dated March 14, 2024, titled "Zydus receives Final Approval from the USFDA for Chlorpromazine Hydrochloride Injection USP, 25 mg/mL and 50 mg/2 mL (25 mg/mL), Single-Dose Vials".